Research publications

Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults

Chee, L

(2021), Transpl. Cell. Ther., 953-954

DOI: 10.1016/j.jtct.2021.10.017

Red blood cell transfusion in patients with anti-Yt(a)

Wong, SM; Cawthorne, T; Dennington, PM; Hong, FS

(2021), Transfusion, 379-384

DOI: 10.1111/trf.16239

Myeloid somatic mutation panel testing in myeloproliferative neoplasms

Ross, DM; Thomson, C; Hamad, N; Lane, SW; Manos, K; Grigg, AP; Guo, B; Erber, WN; Scott, A; Viiala, N; Chee, L; Latimer, M; Tate, C; Grove, C; Perkins, AC; Blombery, P

(2021), Pathology, 339-348

DOI: 10.1016/j.pathol.2021.01.003

Immature platelet fraction as a predictor of platelet count recovery following allogeneic bone marrow

Grabek, J; D'Elia, N; Kelsey, G

(2021), Pathology, 493-497

DOI: 10.1016/j.pathol.2020.09.031

Identification and quantitation of blasts in myeloid malignancies with marrow fibrosis or marrow hypoplasia and CD34 negativity

Nedumannil, R; Sim, S; Westerman, D; Juneja, S

(2021), Pathology, 795-798

DOI: 10.1016/j.pathol.2020.10.022

Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy

Leitinger, EJ; Wright, RM; Nelson, N; Anderson, MA; Juneja, S

(2021), Pathology, 926-929

DOI: 10.1016/j.pathol.2021.01.013

Diagnosis of rare subtypes of acute myeloid leukaemia and related neoplasms

George, TI; Bajel, A

(2021), Pathology, 312-327

DOI: 10.1016/j.pathol.2021.02.001

CAR-T cell therapy: practical guide to routine laboratory monitoring

Selim, AG; Minson, A; Blombery, P; Dickinson, M; Harrison, SJ; Anderson, MA

(2021), Pathology, 408-415

DOI: 10.1016/j.pathol.2021.02.002

Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding

Kuzich, JA; Heynemann, S; Geoghegan, N; Evelyn, C; O'Mahoney, S; Wilson, S; Campbell, J; Rogers, K; Solomon, B; Westerman, D; Pasricha, SR

(2021), Pathology, 608-612

DOI: 10.1016/j.pathol.2020.10.023

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Hillmen, P; Szer, J; Weitz, I; Roth, A; Hochsmann, B; Panse, J; Usuki, K; Griffin, M; Kiladjian, JJ; de Castro, C; Nishimori, H; Tan, L; Hamdani, M; Deschatelets, P; Francois, C; Grossi, F; Ajayi, T; Risitano, A; de la Tour, RP

(2021), N. Engl. J. Med., 1028-1037

DOI: 10.1056/NEJMoa2029073

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

Giuffrida, L; Sek, K; Henderson, MA; Lai, JY; Chen, AXY; Meyran, D; Todd, KL; Petley, EV; Mardiana, S; Molck, C; Stewart, GD; Solomon, BJ; Parish, IA; Neeson, PJ; Harrison, SJ; Kats, LM; House, IG; Darcy, PK; Beavis, PA

(2021), Nat. Commun.

DOI: 10.1038/s41467-021-23331-5

Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study

Lim, C; Sinha, P; Harrison, SJ; Quach, H; Slavin, MA; Teh, BW

(2021), Mycoses, 30-34

DOI: 10.1111/myc.13178

Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition

Hogg, SJ; Motorna, O; Cluse, LA; Johanson, TM; Coughlan, HD; Raviram, R; Myers, RM; Costacurta, M; Todorovski, I; Pijpers, L; Bjelosevic, S; Williams, T; Huskins, SN; Kearney, CJ; Devlin, JR; Fan, Z; Jabbari, JS; Martin, BP; Fareh, M; Kelly, MJ; Dupere-Richer, D; Sandow, JJ; Feran, B; Knight, D; Khong, T; Spencer, A; Harrison, SJ; Gregory, G; Wickramasinghe, VO; Webb, AI; Taberlay, PC; Bromberg, KD; Lai, A; Papenfuss, AT; Smyth, GK; Allan, RS; Licht, JD; Landau, DA; Abdel-Wahab, O; Shortt, J; Vervoort, SJ; Johnstone, RW

(2021), Mol. Cell, 2183

DOI: 10.1016/j.molcel.2021.04.015

Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study

Yee, K; Papayannidis, C; Vey, N; Dickinson, MJ; Kelly, KR; Assouline, S; Kasner, M; Seiter, K; Drummond, MW; Yoon, SS; Lee, JH; Blotner, S; Jukofsky, L; Pierceall, WE; Zhi, JG; Simon, S; Higgins, B; Nichols, G; Monnet, A; Muehlbauer, S; Ott, M; Chen, LC; Martinelli, G

(2021), Leuk. Res.

DOI: 10.1016/j.leukres.2020.106489

Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH

Singh, J; Facey, A; O'Malley, F; Ryland, GL; Blombery, P; Gregory, GP

(2021), Leuk. Lymphoma, 3060-3062

DOI: 10.1080/10428194.2021.1941935

Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL

Jobson, D; McCormack, CJ; Hiscutt, E; Tam, C

(2021), Leuk. Lymphoma, 992-994

DOI: 10.1080/10428194.2020.1846735

Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature

Reynolds, G; Stewart, T; Harrison, SJ; Spencer, A; Teh, BW

(2021), Leuk. Lymphoma, 1271-1274

DOI: 10.1080/10428194.2020.1855343

Too much, or not enough? The enduring uncertainty of maintenance rituximab for transformed follicular lymphoma COMMENT

Minson, A; Dickinson, M

(2021), Leuk. Lymphoma, 2047-2049

DOI: 10.1080/10428194.2021.1938033

The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL

Seymour, JF

(2021), Leuk. Lymphoma, 2299-2302

DOI: 10.1080/10428194.2021.1984462

RT or not RT? The question for early-stage peripheral T-cell lymphoma

Campbell, BA; Khot, A

(2021), Leuk. Lymphoma, 511-513

DOI: 10.1080/10428194.2021.1876873

Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN

Caldwell, I; Byrne, D; Lade, S; Akhurst, T; Minson, A; Dickinson, M; Thompson, E; Scott, C; Blombery, P

(2021), Leuk. Lymphoma, 3521-3525

DOI: 10.1080/10428194.2021.1965139

Glofitamab CD20-TCB bispecific antibody

Minson, A; Dickinson, M

(2021), Leuk. Lymphoma, 3098-3108

DOI: 10.1080/10428194.2021.1953016

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

Kalff, A; Khong, T; Ramachandran, M; Walker, P; Schwarer, A; Roberts, AW; Campbell, P; Filshie, R; Norton, S; Reynolds, J; Young, M; Pierceall, W; Thakurta, A; Guo, MM; Oppermann, U; Wang, M; Ren, Y; Kennedy, N; Parekh, S; Spencer, A

(2021), Leuk. Lymphoma, 2981-2991

DOI: 10.1080/10428194.2021.1948030

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Dimopoulos, MA; Leleu, X; Moreau, P; Richardson, PG; Liberati, AM; Harrison, SJ; Prince, HM; Ocio, EM; Assadourian, S; Campana, F; Malinge, L; Semiond, D; van de Velde, H; Yong, K

(2021), Leukemia, 562-572

DOI: 10.1038/s41375-020-0868-z

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Grever, M; Andritsos, L; Banerji, V; Barrientos, JC; Bhat, S; Blachly, JS; Call, T; Cross, M; Dearden, C; Demeter, J; Dietrich, S; Falini, B; Forconi, F; Gladstone, DE; Gozzetti, A; Iyengar, S; Johnston, JB; Juliusson, G; Kraut, E; Kreitman, RJ; Lauria, F; Lozanski, G; Parikh, SA; Park, J; Polliack, A; Ravandi, F; Robak, T; Rogers, KA; Saven, A; Seymour, JF; Tadmor, T; Tallman, MS; Tam, CS; Tiacci, E; Troussard, X; Zent, C; Zenz, T; Zinzani, PL; Wormann, B

(2021), Leukemia, 1864-1872

DOI: 10.1038/s41375-021-01257-7

Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia

Wei, AH; Ribera, JM; Larson, RA; Ritchie, D; Ghobadi, A; Chen, YQ; Anderson, A; Dos Santos, CE; Franklin, J; Kantarjian, H

(2021), Leukemia, 2220-2231

DOI: 10.1038/s41375-020-01089-x

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Moreau, P; Kumar, SK; San Miguel, J; Davies, F; Zamagni, E; Bahlis, N; Ludwig, H; Mikhael, J; Terpos, E; Schjesvold, F; Martin, T; Yong, K; Durie, BGM; Facon, T; Jurczyszyn, A; Sidana, S; Raje, N; van de Donk, N; Lonial, S; Cavo, M; Kristinsson, SY; Lentzsch, S; Hajek, R; Anderson, KC; Joao, C; Einsele, H; Sonneveld, P; Engelhardt, M; Fonseca, R; Vangsted, A; Weisel, K; Baz, R; Hungria, V; Berdeja, JG; da Costa, FL; Maiolino, A; Waage, A; Vesole, DH; Ocio, EM; Quach, H; Driessen, C; Blade, J; Leleu, X; Riva, E; Bergsagel, PL; Hou, J; Chng, WJ; Mellqvist, UH; Dytfeld, D; Harousseau, JL; Goldschmidt, H; Laubach, J; Munshi, NC; Gay, F; Beksac, M; Costa, LJ; Kaiser, M; Hari, P; Boccadoro, M; Usmani, SZ; Zweegman, S; Holstein, S; Sezer, O; Harrison, S; Nahi, H; Cook, G; Mateos, MV; Rajkumar, SV; Dimopoulos, MA; Richardson, PG

(2021), Lancet Oncol., E105-E118

DOI: 10.1016/S1470-2045(20)30756-7

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Schuster, SJ; Tam, CS; Borchmann, P; Worel, N; McGuirk, JP; Holte, H; Waller, EK; Jaglowski, S; Bishop, MR; Damon, LE; Foley, SR; Westin, JR; Fleury, I; Ho, PJ; Mielke, S; Teshima, T; Janakiram, M; Hsu, JM; Izutsu, K; Kersten, MJ; Ghosh, M; Wagner-Johnston, N; Kato, K; Corradini, P; Martinez-Prieto, M; Han, X; Tiwari, R; Salles, G; Maziarz, RT

(2021), Lancet Oncol., 1403-1415

DOI: 10.1016/S1470-2045(21)00375-2

Vaccine efficacy and iron deficiency: an intertwined pair?

Drakesmith, H; Pasricha, SR; Cabantchik, I; Hershko, C; Weiss, G; Girelli, D; Stoffel, N; Muckenthaler, MU; Nemeth, E; Camaschella, C; Klenerman, P; Zimmermann, MB

(2021), Lancet Haematol., E666-E669

DOI: 10.1016/S2352-3026(21)00201-5

Finding ferritin in the plateaus and valleys of iron deficiency

Braat, S; Pasricha, SR

(2021), Lancet Haematol., E539-E540

DOI: 10.1016/S2352-3026(21)00196-4